JP2024504777A5 - - Google Patents
Info
- Publication number
- JP2024504777A5 JP2024504777A5 JP2023545809A JP2023545809A JP2024504777A5 JP 2024504777 A5 JP2024504777 A5 JP 2024504777A5 JP 2023545809 A JP2023545809 A JP 2023545809A JP 2023545809 A JP2023545809 A JP 2023545809A JP 2024504777 A5 JP2024504777 A5 JP 2024504777A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- subunit
- nanocage
- item
- monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142704P | 2021-01-28 | 2021-01-28 | |
| US63/142,704 | 2021-01-28 | ||
| PCT/CA2022/050122 WO2022160057A1 (en) | 2021-01-28 | 2022-01-28 | Multabody constructs, compositions, and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504777A JP2024504777A (ja) | 2024-02-01 |
| JP2024504777A5 true JP2024504777A5 (cg-RX-API-DMAC7.html) | 2025-02-04 |
Family
ID=82652697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023545809A Pending JP2024504777A (ja) | 2021-01-28 | 2022-01-28 | Multabody構築物、組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240317842A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4284840A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024504777A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230136166A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117157328A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022212978A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3208446A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023008912A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022160057A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4370558A4 (en) * | 2021-07-12 | 2025-09-10 | Hospital For Sick Children | OPTIMIZED MULTIBODY CONSTRUCTS, COMPOSITIONS AND METHODS |
| MX2024003140A (es) * | 2021-09-13 | 2024-06-24 | Hospital For Sick Children | Construcciones, composiciones y metodos de multabody optimizados. |
| US20250002564A1 (en) * | 2021-10-16 | 2025-01-02 | The Hospital For Sick Children | Modified multabody constructs, compositions, and methods |
| EP4416189A4 (en) * | 2021-10-16 | 2025-08-27 | Hospital For Sick Children | MODIFIED MULTIBODY CONSTRUCTS, COMPOSITIONS AND METHODS TARGETING SARS-CoV-2 |
| EP4634238A1 (en) * | 2022-12-18 | 2025-10-22 | Radiant Biotherapeutics Inc. | Multivalent hematopoietic cell engagers or activators |
| CN120771308B (zh) * | 2025-09-04 | 2025-12-12 | 中山大学 | 一种具有缓释效应的蛋白笼纳米药物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008048288A2 (en) * | 2005-11-09 | 2008-04-24 | Montana State University | Novel nanoparticles and use thereof |
| BR112017014219A2 (en) * | 2014-12-31 | 2018-03-06 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | multivalent nanoparticle-based vaccines |
| CA3071922A1 (en) * | 2017-08-04 | 2019-02-07 | The Governing Council Of The University Of Toronto | Nanoparticle platform for antibody and vaccine delivery |
| CN113395978A (zh) * | 2018-07-11 | 2021-09-14 | 动量制药公司 | 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| AU2020315598B2 (en) * | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| CA3149320A1 (en) * | 2019-08-01 | 2021-02-04 | The Hospital For Sick Children | Multi-valent and multi-specific nanoparticle platforms and methods |
| MX2023004023A (es) * | 2020-10-09 | 2023-07-07 | Hospital For Sick Children | Polipéptidos que eligen como objetivo a sars-cov-2 y composiciones y métodos relacionados. |
-
2022
- 2022-01-28 CN CN202280021845.1A patent/CN117157328A/zh active Pending
- 2022-01-28 AU AU2022212978A patent/AU2022212978A1/en active Pending
- 2022-01-28 MX MX2023008912A patent/MX2023008912A/es unknown
- 2022-01-28 US US18/263,217 patent/US20240317842A1/en active Pending
- 2022-01-28 WO PCT/CA2022/050122 patent/WO2022160057A1/en not_active Ceased
- 2022-01-28 KR KR1020237028653A patent/KR20230136166A/ko active Pending
- 2022-01-28 CA CA3208446A patent/CA3208446A1/en active Pending
- 2022-01-28 EP EP22744974.1A patent/EP4284840A4/en active Pending
- 2022-01-28 JP JP2023545809A patent/JP2024504777A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7328267B2 (ja) | Hiv感染症の予防または処置のための三重特異性および/または三価結合タンパク質 | |
| US20230357401A1 (en) | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection | |
| JP6104121B2 (ja) | 操作されたヘテロ二量体タンパク質ドメイン | |
| JP6772157B2 (ja) | インフルエンザヘマグルチニンに対する結合分子及びその使用 | |
| JP2019519527A (ja) | 操作されたFcコンストラクトに関する組成物及び方法 | |
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP2023544211A5 (cg-RX-API-DMAC7.html) | ||
| JP2022543070A5 (cg-RX-API-DMAC7.html) | ||
| JP2017523814A5 (cg-RX-API-DMAC7.html) | ||
| CA3232349A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| JP2019502694A (ja) | 二特異性抗体基幹 | |
| CN110234355A (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| JP7676316B2 (ja) | Hiv感染症の処置のためのクロスオーバー二重可変ドメイン(codv)フォーマットを使用した三重特異性および/または三価結合性タンパク質 | |
| US10344078B2 (en) | Type III secretion system targeting molecules | |
| JP2024504777A (ja) | Multabody構築物、組成物および方法 | |
| JP2021512159A5 (cg-RX-API-DMAC7.html) | ||
| US20250197481A1 (en) | Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV | |
| BR112019013955A2 (pt) | Composições e métodos relacionados a construtos de fc manipulados | |
| JP2024541905A (ja) | 人工操作Fcバリアント | |
| JP2023550191A5 (cg-RX-API-DMAC7.html) | ||
| US20220144956A1 (en) | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII | |
| US20130189247A1 (en) | Multimeric Proteins Comprising Immunoglobulin Constant Domains | |
| Wang et al. | New directions for half-life extension of protein therapeutics: the rise of antibody Fc domains and fragments | |
| BR112021000393A2 (pt) | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado | |
| JP2024525691A5 (cg-RX-API-DMAC7.html) |